# Todd A Fehniger

List of Publications by Year
in descending order



| 167 | 16,814 | 38742 50 | 15732 125 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 173 | 173 | 173 | 20086 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The biology of human natural killer-cell subsets. Trends in Immunology, 2001, 22, 633-640. | 6.8 | 2,520 |
| 2 | Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood, 2001, 97, 3146-3151. | 1.4 | 1,201 |
| 3 | Interleukin 15: biology and relevance to human disease. Blood, 2001, 97, 14-32. | 1.4 | 851 |
| 4 | Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 2019, 49, 1457-1973. | 2.9 | 766 |
| 5 | CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood, 2003, 101, 3052-3057. | 1.4 | 750 |
| 6 | Granzyme B and Perforin Are Important for Regulatory T Cell-Mediated Suppression of Tumor Clearance. Immunity, 2007, 27, 635-646. | 14.3 | 715 |
| 7 | TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. New England Journal of Medicine, 2016, 375, 2023-2036. | 27.0 | 663 |
| 8 | Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Science Translational Medicine, 2016, 8, 357ra123. | 12.4 | 621 |
| 9 | Guidelines for the use of flow cytometry and cell sorting in immunological studies<sup>*</sup>. European Journal of Immunology, 2017, 47, 1584-1797. | 2.9 | 505 |
| 10 | Cytokine activation induces human memory-like NK cells. Blood, 2012, 120, 4751-4760. | 1.4 | 492 |
| 11 | Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood, 2002, 100, 1935-1947. | 1.4 | 449 |
| 12 | NK cell and DC interactions. Trends in Immunology, 2004, 25, 47-52. | 6.8 | 395 |
| 13 | Acquisition of Murine NK Cell Cytotoxicity Requires the Translation of a Pre-existing Pool ofÂGranzyme B and Perforin mRNAs. Immunity, 2007, 26, 798-811. | 14.3 | 391 |
| 14 | In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood, 2002, 100, 3633-3638. | 1.4 | 382 |
| 15 | Fatal Leukemia in Interleukin 15 Transgenic Mice Follows Early Expansions in Natural Killer and Memory Phenotype Cd8+ T Cells. Journal of Experimental Medicine, 2001, 193, 219-232. | 8.5 | 335 |
| 16 | First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood, 2018, 131, 2515-2527. | 1.4 | 307 |
| 17 | Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine and Growth Factor Reviews, 2002, 13, 169-183. | 7.2 | 251 |
| 18 | CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. Journal of Clinical Investigation, 2017, 127, 4042-4058. | 8.2 | 236 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer Cells. Biology of Blood and Marrow Transplantation, 2014, 20, 463-473. | 2.0 | 215 |
| 20 | Flt3 Ligand Promotes the Generation of a Distinct CD34+Human Natural Killer Cell Progenitor That Responds to Interleukin-15. Blood, 1998, 92, 3647-3657. | 1.4 | 198 |
| 21 | A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood, 2011, 118, 5119-5125. | 1.4 | 181 |
| 22 | Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood, 2017, 129, 473-483. | 1.4 | 147 |
| 23 | Next-generation sequencing identifies the natural killer cell microRNA transcriptome. Genome Research, 2010, 20, 1590-1604. | 5.5 | 144 |
| 24 | Severe Cytokine-Release Syndrome after T Cellâ€“Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Antiâ€“IL-6 Therapy Is Safe and Well Tolerated. Biology of Blood and Marrow Transplantation, 2016, 22, 1851-1860. | 2.0 | 135 |
| 25 | CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood, 2020, 136, 2308-2318. | 1.4 | 133 |
| 26 | The IL-15-Based ALT-803 Complex Enhances FcÎ³RIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. Clinical Cancer Research, 2016, 22, 596-608. | 7.0 | 130 |
| 27 | Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood, 2018, 131, 182-190. | 1.4 | 130 |
| 28 | CD56bright natural killer cell subsets: Characterization of distinct functional responses to interleukin-2 and the c-kit ligand. European Journal of Immunology, 1997, 27, 354-360. | 2.9 | 108 |
| 29 | A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood, 2011, 117, 1828-1833. | 1.4 | 104 |
| 30 | Utilizing Cytokines to Function-Enable Human NK Cells for the Immunotherapy of Cancer. Scientifica, 2014, 2014, 1-18. | 1.7 | 104 |
| 31 | Biology and clinical impact of human natural killer cells. International Journal of Hematology, 2003, 78, 7-17. | 1.6 | 93 |
| 32 | Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1646-1652. | 2.0 | 92 |
| 33 | Harnessing NK Cell Memory for Cancer Immunotherapy. Trends in Immunology, 2016, 37, 877-888. | 6.8 | 90 |
| 34 | Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control. JCI Insight, 2017, 2, . | 5.0 | 90 |
| 35 | Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2014, 20, 46-52. | 2.0 | 86 |
| 36 | Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. Journal of Clinical Investigation, 2000, 106, 117-124. | 8.2 | 85 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. Cancer Discovery, 2020, 10, 1854-1871. | 9.4 | 83 |
| 38 | Human Cytokine-Induced Memory-Like Natural Killer Cells. Journal of Innate Immunity, 2015, 7, 563-571. | 3.8 | 81 |
| 39 | Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunology, Immunotherapy, 1998, 46, 318-326. | 4.2 | 79 |
| 40 | Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood, 2009, 113, 1002-1005. | 1.4 | 79 |
| 41 | Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neuropathologica, 2017, 133, 61-77. | 7.7 | 72 |
| 42 | Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Bloodâ€“Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. Clinical Cancer Research, 2021, 27, 3744-3756. | 7.0 | 69 |
| 43 | Complete characterization of the microRNAome in a patient with acute myeloid leukemia. Blood, 2010, 116, 5316-5326. | 1.4 | 63 |
| 44 | Potently Cytotoxic Natural Killer Cells Initially Emerge from Erythro-Myeloid Progenitors during Mammalian Development. Developmental Cell, 2020, 53, 229-239.e7. | 7.0 | 63 |
| 45 | Latent herpesvirus infection arms NK cells. Blood, 2010, 115, 4377-4383. | 1.4 | 62 |
| 46 | MicroRNA-Deficient NK Cells Exhibit Decreased Survival but Enhanced Function. Journal of Immunology, 2012, 188, 3019-3030. | 0.8 | 62 |
| 47 | A deep learning approach to automate refinement of somatic variant calling from cancer sequencing data. Nature Genetics, 2018, 50, 1735-1743. | 21.4 | 62 |
| 48 | Cutting Edge: IL-15 Costimulates the Generalized Shwartzman Reaction and Innate Immune IFN-Î³ Production In Vivo. Journal of Immunology, 2000, 164, 1643-1647. | 0.8 | 59 |
| 49 | Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis. Science Translational Medicine, 2020, 12, . | 12.4 | 57 |
| 50 | Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant. Blood, 2022, 139, 1670-1683. | 1.4 | 57 |
| 51 | Lenalidomide-mediated enhanced translation of C/EBPÎ±-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood, 2013, 121, 159-169. | 1.4 | 56 |
| 52 | Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. Haematologica, 2016, 101, e465-e468. | 3.5 | 54 |
| 53 | MicroRNA regulation of natural killer cells. Frontiers in Immunology, 2013, 4, 44. | 4.8 | 53 |
| 54 | MicroRNA-155 Tunes Both the Threshold and Extent of NK Cell Activation via Targeting of Multiple Signaling Pathways. Journal of Immunology, 2013, 191, 5904-5913. | 0.8 | 51 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review. Biology of Blood and Marrow Transplantation, 2016, 22, 1696-1701. | 2.0 | 50 |
| 56 | A Phase 1 Trial of CNDO-109â€“Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 1581-1589. | 2.0 | 50 |
| 57 | Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. Science Translational Medicine, 2022, 14, eabm1375. | 12.4 | 49 |
| 58 | Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and FcÎ³RIIIa-Triggered Responses. Biology of Blood and Marrow Transplantation, 2017, 23, 398-404. | 2.0 | 48 |
| 59 | Memory-like natural killer cells for cancer immunotherapy. Seminars in Hematology, 2020, 57, 185-193. | 3.4 | 48 |
| 60 | Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. Journal of Geriatric Oncology, 2015, 6, 211-218. | 1.0 | 47 |
| 61 | Improving natural killer cell cancer immunotherapy. Current Opinion in Organ Transplantation, 2015, 20, 671-680. | 1.6 | 44 |
| 62 | MicroRNA-15/16 Antagonizes Myb To Control NK Cell Maturation. Journal of Immunology, 2015, 195, 2806-2817. | 0.8 | 44 |
| 63 | Fatal Leukemia in Interleukin-15 Transgenic Mice. Blood Cells, Molecules, and Diseases, 2001, 27, 223-230. | 1.4 | 43 |
| 64 | KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. Blood Advances, 2020, 4, 740-754. | 5.2 | 42 |
| 65 | Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. Blood, 2022, 139, 1177-1183. | 1.4 | 41 |
| 66 | Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and Cytotoxicity. Cell Reports, 2020, 31, 107720. | 6.4 | 40 |
| 67 | Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clinical Cancer Research, 2002, 8, 2812-9. | 7.0 | 40 |
| 68 | MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis. Cancer Research, 2018, 78, 3510-3521. | 0.9 | 39 |
| 69 | MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells. Immunity, 2019, 51, 479-490.e6. | 14.3 | 39 |
| 70 | T Cellâ€“Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 648-653. | 2.0 | 38 |
| 71 | Differential Expression of Granzyme B and C in Murine Cytotoxic Lymphocytes. Journal of Immunology, 2009, 182, 6287-6297. | 0.8 | 37 |
| 72 | micro<scp>RNA</scp> management of <scp>NK</scp>â€cell developmental and functional programs. European Journal of Immunology, 2014, 44, 2862-2868. | 2.9 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy. Cancer Immunology Research, 2021, 9, 1071-1087. | 3.4 | 36 |
| 74 | PTEN regulates natural killer cell trafficking in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E700-E709. | 7.1 | 34 |
| 75 | Ontogeny and Expansion of Human Natural Killer Cells: Clinical Implications. International Reviews of Immunology, 2001, 20, 503-536. | 3.3 | 33 |
| 76 | Memory-like Differentiation Enhances NK Cell Responses to Melanoma. Clinical Cancer Research, 2021, 27, 4859-4869. | 7.0 | 33 |
| 77 | Stem Cell Factor Enhances Interleukin-2â€“Mediated Expansion of Murine Natural Killer Cells In Vivo. Blood, 1997, 90, 3647-3653. | 1.4 | 32 |
| 78 | New directions in natural killer cell-based immunotherapy of human cancer. Expert Opinion on Biological Therapy, 2003, 3, 237-250. | 3.1 | 32 |
| 79 | Natural Killer Cell Regulation by MicroRNAs in Health and Disease. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-12. | 3.0 | 30 |
| 80 | CD56 regulates human NK cell cytotoxicity through Pyk2. ELife, 2020, 9, . | 6.0 | 30 |
| 81 | Granzyme B is not required for regulatory T cellâ€“mediated suppression of graft-versus-host disease. Blood, 2010, 115, 1669-1677. | 1.4 | 29 |
| 82 | Human Adaptive Natural Killer Cells: Beyond NKG2C. Trends in Immunology, 2016, 37, 351-353. | 6.8 | 27 |
| 83 | Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clinical Cancer Research, 2021, 27, 3339-3350. | 7.0 | 26 |
| 84 | T Cellâ€“Depleted Partial Matched Unrelated Donor Transplant for Advanced Myeloid Malignancy: KIR Ligand Mismatch and Outcome. Biology of Blood and Marrow Transplantation, 2012, 18, 937-943. | 2.0 | 25 |
| 85 | Transcriptional and post-transcriptional regulation of NK cell development and function. Clinical Immunology, 2017, 177, 60-69. | 3.2 | 23 |
| 86 | A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 347-353. | 0.4 | 23 |
| 87 | Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10â€day decitabine regimen. Cancer Medicine, 2017, 6, 2814-2821. | 2.8 | 21 |
| 88 | Hop Cleavage and Function in Granzyme B-induced Apoptosis. Journal of Biological Chemistry, 2006, 281, 37130-37141. | 3.4 | 19 |
| 89 | Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplant (HCT). Blood, 2019, 134, 1954-1954. | 1.4 | 19 |
| 90 | Natural killer cells: biology and application in stem-cell transplantation. Cytotherapy, 2002, 4, 445-446. | 0.7 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Phase 1/dose expansion trial of brentuximab vedotin andÂlenalidomide in relapsed or refractory diffuse large B-cell lymphoma. Blood, 2022, 139, 1999-2010. | 1.4 | 17 |
| 92 | Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advances, 2018, 2, 1705-1718. | 5.2 | 16 |
| 93 | Reliance on Cox10 and oxidative metabolism for antigen-specific NK cell expansion. Cell Reports, 2021, 35, 109209. | 6.4 | 16 |
| 94 | Human NK cells: SET to kill. Blood, 2011, 117, 2297-2298. | 1.4 | 13 |
| 95 | Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. Biology of Blood and Marrow Transplantation, 2015, 21, 1425-1430. | 2.0 | 12 |
| 96 | A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.. Blood, 2009, 114, 3693-3693. | 1.4 | 12 |
| 97 | Interleukin-15 superagonist (N-803) treatment of PML and JCV in a postâ€“allogeneic hematopoietic stem cell transplant patient. Blood Advances, 2020, 4, 2387-2391. | 5.2 | 11 |
| 98 | Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after Hematopoietic Cell Transplantation. Blood, 2019, 134, 3307-3307. | 1.4 | 9 |
| 99 | Human Cytokine-Induced Memory-like (CIML) NK Cells Are Active Against Myeloid Leukemia in Vitro and in Vivo. Blood, 2014, 124, 1117-1117. | 1.4 | 9 |
| 100 | Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a029512. | 5.5 | 8 |
| 101 | Comment on: Evidence of innate lymphoid cell redundancy in humans. Nature Immunology, 2018, 19, 788-789. | 14.5 | 8 |
| 102 | Flow cytometry-based ex vivo murine NK cell cytotoxicity assay. STAR Protocols, 2021, 2, 100262. | 1.2 | 8 |
| 103 | Phase II Study of High Dose Lenalidomide as Initial Treatment for Older Acute Myeloid Leukemia Patients: Early Results Show a Significant Reduction of Bone Marrow Blasts after 14 Days of Therapy.. Blood, 2007, 110, 916-916. | 1.4 | 8 |
| 104 | A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results. Blood, 2008, 112, 2595-2595. | 1.4 | 8 |
| 105 | Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study. Leukemia and Lymphoma, 2018, 59, 357-362. | 1.3 | 7 |
| 106 | A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma. Blood, 2012, 120, 1623-1623. | 1.4 | 7 |
| 107 | 'First-in-human' phase I dose escalation trial of IL-15N72D/IL-15RÎ±-Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological malignancy. Blood, 2015, 126, 1957-1957. | 1.4 | 7 |
| 108 | Mystery Solved: IL-15. Journal of Immunology, 2019, 202, 3125-3126. | 0.8 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Open-Sourced CIViC Annotation Pipeline to Identify and Annotate Clinically Relevant Variants Using Single-Molecule Molecular Inversion Probes. JCO Clinical Cancer Informatics, 2019, 3, 1-12. | 2.1 | 6 |
| 110 | Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses. Blood, 2019, 134, 3237-3237. | 1.4 | 6 |
| 111 | Chronic lymphocytosis of functionally immature natural killer cells. Journal of Allergy and Clinical Immunology, 2007, 120, 924-931. | 2.9 | 5 |
| 112 | Extracellular microRNAs turn on NK cells via TLR1. Blood, 2013, 121, 4612-4613. | 1.4 | 5 |
| 113 | A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL). Blood, 2012, 120, 1644-1644. | 1.4 | 5 |
| 114 | Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission. Blood, 2014, 124, 2320-2320. | 1.4 | 5 |
| 115 | Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes. Blood, 2015, 126, 1950-1950. | 1.4 | 5 |
| 116 | A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 3988-3988. | 1.4 | 5 |
| 117 | A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cells. Molecular Therapy - Oncolytics, 2022, 24, 585-596. | 4.4 | 5 |
| 118 | Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma. Cancers, 2022, 14, 2932. | 3.7 | 5 |
| 119 | CD70 turns on NK cells to attack lymphoma. Blood, 2017, 130, 238-239. | 1.4 | 4 |
| 120 | A Phase II Study of High Dose Lenalidomide as Initial Therapy for Acute Myeloid Leukemia in Patients > 60 Years Old.. Blood, 2009, 114, 842-842. | 1.4 | 4 |
| 121 | Mir-15/16 Antagonizes Myb To Control Natural Killer Cell Differentiation and Maturation. Blood, 2013, 122, 17-17. | 1.4 | 4 |
| 122 | Human Cytokine-Induced Memory-like NK Cells Exhibit in Vivo Anti-Leukemia Activity in Xenografted NSG Mice and in Patients with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 101-101. | 1.4 | 4 |
| 123 | Memory NK Cells Take Out the (Mitochondrial) Garbage. Immunity, 2015, 43, 218-220. | 14.3 | 3 |
| 124 | A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2020, 26, 2223-2228. | 2.0 | 3 |
| 125 | IL-15 Primes a Highly Potent Anti-Leukemia Response By CD56bright NK Cells. Blood, 2013, 122, 2283-2283. | 1.4 | 3 |
| 126 | A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkinâ€™s Lymphoma (HL). Blood, 2014, 124, 3099-3099. | 1.4 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | The IL-15 Superagonist ALT-803 Enhances NK Cell ADCC and in Vivo Clearance of B Cell Lymphomas Directed By an Anti-CD20 Monoclonal Antibody. Blood, 2014, 124, 807-807. | 1.4 | 3 |
| 128 | End of Treatment Peripheral Blood T-Cell Receptor Gene Rearrangement Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas. Blood, 2020, 136, 30-31. | 1.4 | 2 |
| 129 | MicroRNA-Deficient Murine NK Cells Exhibit Impaired Development and Survival but Enhanced IFN-Î³ Production In Vitro and In Vivo. Blood, 2011, 118, 357-357. | 1.4 | 2 |
| 130 | Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing. Blood, 2015, 126, 574-574. | 1.4 | 2 |
| 131 | Comprehensive Evaluation of MicroRNA Genes and Gene Expression Using Next Generation Sequencing in a Patient with Acute Myelogenous Leukemia.. Blood, 2009, 114, 271-271. | 1.4 | 2 |
| 132 | End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas. Blood, 2021, 138, 3506-3506. | 1.4 | 2 |
| 133 | â€œAbroGATAedâ€•human NK cell development. Blood, 2013, 121, 2579-2580. | 1.4 | 1 |
| 134 | Unraveling the molecular events leading to the genesis of large granular lymphocytic leukemia reveals a new treatment strategy. Haematologica, 2013, 98, 159-159. | 3.5 | 1 |
| 135 | Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow. Haematologica, 2018, 103, e270-e273. | 3.5 | 1 |
| 136 | Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors. Blood, 2019, 134, 869-869. | 1.4 | 1 |
| 137 | Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation.. Blood, 2009, 114, 3417-3417. | 1.4 | 1 |
| 138 | Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients. Blood, 2015, 126, 689-689. | 1.4 | 1 |
| 139 | Cytokine Activation and CD16 Cross-Linking Leads to the Generation of Human Memory-Like NK Cells. Blood, 2012, 120, 3291-3291. | 1.4 | 1 |
| 140 | Cytokine Activation Induces CD25 Expression and a Signaling-Competent High-Affinity IL-2 Receptor On CD56dim Human NK Cells.. Blood, 2012, 120, 2159-2159. | 1.4 | 1 |
| 141 | Human Cytokine-Induced Memory-Like (CIML) NK Cells Exhibit Potent Anti-Leukemia Cytotoxicity and Maintain Memory-Like Functionality After Adoptive Transfer Into Immunodeficient NOD-SCID-Gc-/- (NSG) Mice. Blood, 2013, 122, 4501-4501. | 1.4 | 1 |
| 142 | Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas. Blood, 2019, 134, 1550-1550. | 1.4 | 1 |
| 143 | Cytokine-Induced Memory-like NK Cells Have a Distinct Single Cell Transcriptional Profile and Persist for Months in Adult and Pediatric Leukemia Patients after Adoptive Transfer. Blood, 2021, 138, 3825-3825. | 1.4 | 1 |
| 144 | A Pilot Study of Acalabrutinib with Bendamustine/Rituximab Followed By Cytarabine/Rituximab (R-ABC) for Untreated Mantle Cell Lymphoma. Blood, 2020, 136, 8-9. | 1.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Ontogeny as a Critical Determinant of Natural Killer Cell Potential and Function. Experimental Hematology, 2018, 64, S106. | 0.4 | 0 |
| 146 | ONTOGENY IS A CRITICAL DETERMINANT OF NATURAL KILLER CELL POTENTIAL AND FUNCTION. Experimental Hematology, 2019, 76, S87. | 0.4 | 0 |
| 147 | 65. Accurate neoantigen prediction depends on mutation position relative to patient-specific MHC anchor locations. Cancer Genetics, 2020, 244, 24-25. | 0.4 | 0 |
| 148 | A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma. Med, 2021, 2, 180-195.e5. | 4.4 | 0 |
| 149 | Abstract SY30-02: NK cells remember: Engineering NK cell memory-like responses for cancer immunotherapy. , 2021, , . | | 0 |
| 150 | Murine NK Cells Require Activation-Dependent Expression of Granzyme B and Perforin To Become Potent Cytotoxic Effectors.. Blood, 2006, 108, 920-920. | 1.4 | 0 |
| 151 | Latent Murine Herpesvirus-4 Infection Arms NK Cells.. Blood, 2009, 114, 3678-3678. | 1.4 | 0 |
| 152 | The NK Cell MicroRNA Transcriptome Defined by Next-Generation Sequencing Identifies IL-15-Signaled Alterations In Mature MiR-223 Expression, and MiR-223 as a Potential Regulator of Murine Granzyme B. Blood, 2010, 116, 104-104. | 1.4 | 0 |
| 153 | PTEN Regulates Natural Killer Cell Trafficking in Vivo. Blood, 2014, 124, 753-753. | 1.4 | 0 |
| 154 | Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. Blood, 2015, 126, 3144-3144. | 1.4 | 0 |
| 155 | T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy. Blood, 2015, 126, 3106-3106. | 1.4 | 0 |
| 156 | Exome Sequencing of Hodgkin's and Non-Hodgkin Composite Lymphomas Identifies Shared Somatic Mutations Indicative of Common Founding Precursors. Blood, 2016, 128, 5285-5285. | 1.4 | 0 |
| 157 | Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant. Blood, 2016, 128, 3419-3419. | 1.4 | 0 |
| 158 | Human CD56bright NK Cells Acquire Potent Anti-Leukemia Functionality Following IL-15 Priming. Blood, 2016, 128, 550-550. | 1.4 | 0 |
| 159 | The Use of CD34+-Selected Stem Cell Boosts Following HLA-Haploidentical Hematopoietic Cell Transplantation. Blood, 2016, 128, 4697-4697. | 1.4 | 0 |
| 160 | Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas Including AITL and DLBCL: Phase I Results. Blood, 2018, 132, 2929-2929. | 1.4 | 0 |
| 161 | Ontogeny As a Critical Determinant of Natural Killer Cell Potential and Function. Blood, 2018, 132, 1271-1271. | 1.4 | 0 |
| 162 | System-Level Disease-Driven Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma Associated with Poor Survival. Blood, 2019, 134, 2897-2897. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Potently Cytotoxic Natural Killer Cell Potential Initially Emerges from Erythro-Myeloid Progenitors during Mammalian Development. Blood, 2019, 134, 2464-2464. | 1.4 | 0 |
| 164 | In Vivo Murine Cytokine Models and the Genesis of Cancer. , 2007, , 199-209. | | 0 |
| 165 | Predictors of Relapse and Survival Following Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 1832-1832. | 1.4 | 0 |
| 166 | Eomes and T-Bet Expression Are Required By Mature Primary Human NK Cells for Anti-Leukemia Responses In Vivo. Blood, 2021, 138, 194-194. | 1.4 | 0 |
| 167 | 531â€…AFM13-targeted blood and cord-blood-derived memory-like NK cells as therapy for CD30+ malignancies. , 2020, , . | | 0 |